Page last updated: 2024-10-30

losartan and Liver Cirrhosis

losartan has been researched along with Liver Cirrhosis in 51 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.

Research Excerpts

ExcerptRelevanceReference
" We investigated the effects of losartan on hepatic expression of fibrogenic, inflammatory, and NOX genes in patients with chronic hepatitis C (CHC)."9.14Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. ( Arroyo, V; Bataller, R; Brenner, DA; Bruguera, M; Colmenero, J; Domínguez, M; Forns, X; Ginès, P; Moreno, M; Sancho-Bru, P, 2009)
"Losartan 4 mg/kg/day did not increase renal sodium excretion in this model of liver cirrhosis, although the urinary ANGII excretion was increased."7.88Activation of RAAS in a rat model of liver cirrhosis: no effect of losartan on renal sodium excretion. ( Bie, P; Fialla, AD; Schaffalitzky de Muckadell, OB; Thiesson, HC, 2018)
" Low-grade chronic liver failure (CLF) was induced in 3-month old Sprague-Dawley male rats using thioacetamide (TAA, 50 mg·kg-1·day-1) intraperitoneally for 2 weeks."7.85Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats. ( Ali, SS; Gazzaz, ZJ; Ibraheem, MS; Murad, HA, 2017)
"To evaluate the safety and efficacy of chronic administration of losartan on hepatic fibrosis in chronic hepatitis C patients."7.73Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study. ( Castaño, G; Fernández, MA; Sookoian, S, 2005)
" The aim of this randomised controlled trial was to assess whether treatment with Losartan for 96 weeks slowed, halted or reversed the progression of fibrosis in patients with non-alcoholic steatohepatitis (NASH)."5.24A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. ( Anstee, QM; Barnes, J; Burt, AD; Bury, Y; Day, CP; Goudie, N; Mann, D; McColl, E; McPherson, S; Steen, N; Stewart, S; Stocken, DD; Tiniakos, D; Wilkinson, J; Wilkinson, N, 2017)
" We investigated the effects of losartan on hepatic expression of fibrogenic, inflammatory, and NOX genes in patients with chronic hepatitis C (CHC)."5.14Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. ( Arroyo, V; Bataller, R; Brenner, DA; Bruguera, M; Colmenero, J; Domínguez, M; Forns, X; Ginès, P; Moreno, M; Sancho-Bru, P, 2009)
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."4.21 ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)
"Losartan 4 mg/kg/day did not increase renal sodium excretion in this model of liver cirrhosis, although the urinary ANGII excretion was increased."3.88Activation of RAAS in a rat model of liver cirrhosis: no effect of losartan on renal sodium excretion. ( Bie, P; Fialla, AD; Schaffalitzky de Muckadell, OB; Thiesson, HC, 2018)
" Low-grade chronic liver failure (CLF) was induced in 3-month old Sprague-Dawley male rats using thioacetamide (TAA, 50 mg·kg-1·day-1) intraperitoneally for 2 weeks."3.85Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats. ( Ali, SS; Gazzaz, ZJ; Ibraheem, MS; Murad, HA, 2017)
"We performed a longitudinal study that included 23 consecutive patients with cirrhosis and esophageal varices who received 25 mg/day of losartan during 12 wk."3.73A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. ( Castaño, G; García, SI; González, C; Pirola, CJ; Sookoian, S; Viudez, P, 2005)
"To evaluate the safety and efficacy of chronic administration of losartan on hepatic fibrosis in chronic hepatitis C patients."3.73Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study. ( Castaño, G; Fernández, MA; Sookoian, S, 2005)
"The therapeutic efficacy of angiotensin II receptor antagonist, losartan, was studied in patients with nonalcoholic steatohepatitis (NASH)."3.72Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. ( Aso, K; Haneda, M; Hasegawa, T; Miyokawa, N; Nakamura, K; Okada, M; Okamoto, S; Tokusashi, Y; Yokohama, S; Yoneda, M, 2004)
"Hydrostatic pressure-induced liver fibrosis model was established in mice by ligating partially the inferior vena cava, and then randomly received a very low dose of losartan (0."3.11Angiotensin receptor blocker alleviates liver fibrosis by altering the mechanotransduction properties of hepatic stellate cells. ( Gu, W; Huang, Y; Huang, Z; Khalifa, MO; Li, P; Li, TS, 2022)
"Although viral hepatocellular carcinoma (HCC) is declining, nonviral HCC, which often is the end stage of nonalcoholic or alcoholic steatohepatitis (NASH, ASH), is on an upward trajectory."1.91Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. ( Chamseddine, S; Gu, L; Huang, JY; Karin, M; Kaseb, AO; Lee, M; Mohamed, YI; Nguyen, A; Pandit, SK; Ryujin, NT; Shalapour, S; Xiao, L; Zhu, Y, 2023)
"Schistosomiasis mansoni is involved in hepatic fibrogenesis and portal hypertension."1.48The comparative efficacy of renin-angiotensin system blockers in schistosomal hepatic fibrosis. ( Augusto, MJ; Elias Júnior, J; Parreira, NA; Prado, CM; Ramalho, FS; Ramalho, LNZ; Rodrigues, V; Silva, DM, 2018)
"Treatment with losartan suppressed the development of liver fibrosis induced by the CDAA diet, and reduced hepatic periostin expression."1.46Periostin cross‑reacts with the renin‑angiotensin system during liver fibrosis development. ( Aihara, Y; Douhara, A; Kaji, K; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Okura, Y; Sawada, Y; Seki, K; Takeda, K; Yoshiji, H, 2017)
"The effect of YCHD on liver fibrosis and the detailed molecular mechanisms were assessed by liver function including total bilirubin (TBIL), direct bilirubin (DBIL), indirect bilirubin (IDBIL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST)."1.42Effects of Yinchenhao decoction on self-regulation of renin-angiotensin system by targeting angiotensin converting enzyme 2 in bile duct-ligated rat liver. ( Hao, S; Wang, G; Wu, L; Wu, ZX; Xie, JW; Zhou, PQ; Zhou, SC; Zhu, R, 2015)
"An advanced liver fibrosis model was developed using C3H/HeN mice subjected to 20 weeks of prolonged TAA/ethanol weight-adapted treatment."1.42Effectiveness of Losartan-Loaded Hyaluronic Acid (HA) Micelles for the Reduction of Advanced Hepatic Fibrosis in C3H/HeN Mice Model. ( Jeong, YY; Kim, JH; Lee, JH; Moon, MJ; Thomas, RG, 2015)
"ARB markedly inhibited liver fibrosis development along with suppression of the number of Ac-HSC and TGF-β."1.39Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. ( Aihara, Y; Douhara, A; Fukui, H; Kaji, K; Kawaratani, H; Moriya, K; Namisaki, T; Noguchi, R; Shirai, Y; Yoshiji, H, 2013)
"Rats with advanced liver fibrosis due to prolonged bile duct ligation or carbon tetrachloride administration were treated with daily doses of saline, losartan-M6PHSA, M6PHSA or oral losartan during 3 days."1.36Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. ( Arroyo, V; Bataller, R; Beljaars, L; Brenner, DA; Fondevila, C; Ginès, P; Gonzalo, T; Kok, RJ; Lacombe, M; Moreno, M; Poelstra, K; Prakash, J; Sancho-Bru, P; Swart, J; Temming, K; van Beuge, M; van der Hoeven, P, 2010)
"Nonalcoholic steatohepatitis (NASH) is a metabolic disorder of the liver that may evolve into fibrosis or cirrhosis."1.34Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. ( Accatino, L; Aguayo, G; Arrese, M; Duarte, I; Ibañez, P; Miquel, JF; Pizarro, M; Solis, N, 2007)
" We aimed to study both the systemic and portal hemodynamics, and tolerability after chronic administration of losartan, an ANG II receptor antagonist."1.32Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. ( Hayes, PC; Johnston, N; Lui, HF; Therapondos, G; Tripathi, D; Webb, DJ, 2004)
" Higher dosage of losartan had deleterious effects in BDL rats."1.31Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. ( Calès, P; Chappard, D; Croquet, V; Douay, O; Gallois, Y; Moal, F; Oberti, F; Roux, J; Veal, N; Vuillemin, E; Wang, J, 2002)

Research

Studies (51)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (5.88)18.2507
2000's25 (49.02)29.6817
2010's18 (35.29)24.3611
2020's5 (9.80)2.80

Authors

AuthorsStudies
Huang, Z1
Khalifa, MO1
Li, P2
Huang, Y2
Gu, W1
Li, TS1
Namisaki, T3
Kaji, K3
Shimozato, N1
Kaya, D1
Ozutsumi, T1
Tsuji, Y1
Fujinaga, Y1
Kitagawa, K1
Furukawa, M1
Sato, S1
Sawada, Y2
Nishimura, N2
Takaya, H1
Okura, Y2
Seki, K2
Kawaratani, H3
Moriya, K3
Noguchi, R3
Asada, K1
Akahane, T1
Mitoro, A1
Yoshiji, H3
Gu, L1
Zhu, Y2
Lee, M1
Nguyen, A1
Ryujin, NT1
Huang, JY1
Pandit, SK1
Chamseddine, S1
Xiao, L1
Mohamed, YI1
Kaseb, AO1
Karin, M1
Shalapour, S1
Nese, M1
Riboli, G1
Brighetti, G1
Sassi, V1
Camela, E1
Caselli, G1
Sassaroli, S1
Borlimi, R1
Aucoin, M1
Cooley, K1
Saunders, PR1
Carè, J1
Anheyer, D1
Medina, DN1
Cardozo, V1
Remy, D1
Hannan, N1
Garber, A1
Velayos, M1
Muñoz-Serrano, AJ1
Estefanía-Fernández, K1
Sarmiento Caldas, MC1
Moratilla Lapeña, L1
López-Santamaría, M1
López-Gutiérrez, JC1
Li, J1
Zhang, J1
Shen, S1
Zhang, B2
Yu, WW1
Toyoda, H1
Huang, DQ1
Le, MH1
Nguyen, MH1
Huang, R1
Zhu, L1
Wang, J7
Xue, L1
Liu, L2
Yan, X2
Huang, S1
Li, Y6
Xu, T1
Li, C2
Ji, F1
Ming, F1
Zhao, Y2
Cheng, J1
Wang, Y3
Zhao, H1
Hong, S1
Chen, K2
Zhao, XA1
Zou, L1
Sang, D1
Shao, H1
Guan, X1
Chen, X2
Chen, Y4
Wei, J1
Zhu, C1
Wu, C1
Moore, HB1
Barrett, CD1
Moore, EE1
Jhunjhunwala, R1
McIntyre, RC1
Moore, PK1
Hajizadeh, N1
Talmor, DS1
Sauaia, A1
Yaffe, MB1
Liu, C3
Lin, Y1
Dong, Y1
Wu, Y1
Bao, Y1
Yan, H2
Ma, J1
Fernández-Cuadros, ME1
Albaladejo-Florín, MJ1
Álava-Rabasa, S1
Usandizaga-Elio, I1
Martinez-Quintanilla Jimenez, D1
Peña-Lora, D1
Neira-Borrajo, I1
López-Muñoz, MJ1
Rodríguez-de-Cía, J1
Pérez-Moro, OS1
Abdallah, M1
Alsaleh, H1
Baradwan, A1
Alfawares, R1
Alobaid, A1
Rasheed, A1
Soliman, I1
Wendel Garcia, PD1
Fumeaux, T1
Guerci, P1
Heuberger, DM1
Montomoli, J2
Roche-Campo, F1
Schuepbach, RA1
Hilty, MP1
Poloni, TE1
Carlos, AF1
Cairati, M1
Cutaia, C1
Medici, V1
Marelli, E1
Ferrari, D1
Galli, A1
Bognetti, P1
Davin, A1
Cirrincione, A1
Ceretti, A1
Cereda, C1
Ceroni, M1
Tronconi, L1
Vitali, S1
Guaita, A1
Leeds, JS1
Raviprakash, V1
Jacques, T1
Scanlon, N1
Cundall, J1
Leeds, CM1
Riva, A1
Gray, EH1
Azarian, S1
Zamalloa, A1
McPhail, MJW1
Vincent, RP1
Williams, R1
Chokshi, S1
Patel, VC1
Edwards, LA1
Alqarawi, W1
Birnie, DH1
Golian, M1
Nair, GM1
Nery, PB1
Klein, A1
Davis, DR1
Sadek, MM1
Neilipovitz, D1
Johnson, CB1
Green, MS1
Redpath, C1
Miller, DC1
Beamer, P1
Billheimer, D1
Subbian, V1
Sorooshian, A1
Campbell, BS1
Mosier, JM1
Novaretti, JV1
Astur, DC1
Cavalcante, ELB1
Kaleka, CC1
Amaro, JT1
Cohen, M1
Huang, W1
Li, T1
Ling, Y1
Qian, ZP1
Zhang, YY1
Huang, D1
Xu, SB1
Liu, XH1
Xia, L1
Yang, Y3
Lu, SH1
Lu, HZ1
Zhang, R2
Ma, JX1
Tang, S1
Li, CM1
Wan, J1
Wang, JF1
Ma, JQ1
Luo, JJ1
Chen, HY2
Mi, SL1
Chen, SY1
Su, YG1
Ge, JB1
Milheiro, SA1
Gonçalves, J1
Lopes, RMRM1
Madureira, M1
Lobo, L1
Lopes, A1
Nogueira, F1
Fontinha, D1
Prudêncio, M1
M Piedade, MF1
Pinto, SN1
Florindo, PR1
Moreira, R1
Castillo-Lora, J1
Delley, MF1
Laga, SM1
Mayer, JM1
Sutjarit, N1
Thongon, N1
Weerachayaphorn, J1
Piyachaturawat, P1
Suksamrarn, A1
Suksen, K1
Papachristou, DJ1
Blair, HC1
Hu, Y1
Shen, P1
Zeng, N1
Wang, L3
Yan, D1
Cui, L1
Yang, K2
Zhai, C1
Yang, M1
Lao, X1
Sun, J1
Ma, N1
Wang, S1
Ye, W1
Guo, P1
Rahimi, S1
Singh, MP1
Gupta, J1
Nakanishi, I1
Ohkubo, K1
Shoji, Y1
Fujitaka, Y1
Shimoda, K1
Matsumoto, KI1
Fukuhara, K1
Hamada, H1
van der Boom, T1
Gruppen, EG1
Lefrandt, JD1
Connelly, MA1
Links, TP1
Dullaart, RPF1
Berry, JD1
Bedlack, R1
Mathews, D1
Agnese, W1
Apple, S1
Meloncelli, S1
Divizia, M1
Germani, G1
Adefegha, SA1
Bottari, NB1
Leal, DB1
de Andrade, CM1
Schetinger, MR1
Martínez-Velasco, A1
Perez-Ortiz, AC1
Antonio-Aguirre, B1
Martínez-Villaseñor, L1
Lira-Romero, E1
Palacio-Pastrana, C1
Zenteno, JC1
Ramirez, I1
Zepeda-Palacio, C1
Mendoza-Velásquez, C1
Camacho-Ordóñez, A1
Ortiz Bibriesca, DM1
Estrada-Mena, FJ1
Martin, BL1
Thompson, LC1
Kim, YH2
Snow, SJ1
Schladweiler, MC1
Phillips, P1
Harmon, M1
King, C1
Richards, J1
George, I1
Haykal-Coates, N1
Gilmour, MI1
Kodavanti, UP1
Hazari, MS1
Farraj, AK1
Shen, Z1
Zou, Y1
Gao, K1
Lazar, S1
Wurtzel, JGT1
Ma, P1
Goldfinger, LE1
Vukelic, M1
Laloo, A1
Kyttaris, VC1
Chen, R1
Chen, J2
Xun, J1
Hu, Z1
Huang, Q2
Steinhart, C1
Shen, Y1
Lu, H1
Mansuri, A1
Lokhande, K1
Kore, S1
Gaikwad, S1
Nawani, N1
Swamy, KV1
Junnarkar, M1
Pawar, S1
Shaheen, MY1
Basudan, AM1
Niazy, AA1
van den Beucken, JJJP1
Jansen, JA1
Alghamdi, HS1
Gao, Q2
Guo, X1
Cao, Y1
Jia, X1
Xu, S1
Lu, C2
Zhu, H2
Melku, M1
Abebe, G1
Teketel, A1
Asrie, F1
Yalew, A1
Biadgo, B1
Kassa, E1
Damtie, D1
Anlay, DZ1
Ahmed, MFE1
Ramadan, H1
Seinige, D1
Kehrenberg, C1
Abd El-Wahab, A1
Volkmann, N1
Kemper, N1
Schulz, J1
Hu, MY1
Wu, YN1
McEvoy, MP1
Wang, YF1
Cong, WL1
Liu, LP1
Li, XX1
Zhou, CL1
Chen, WM1
Wei, KL1
Tung, SY1
Shen, CH1
Chang, TS1
Yen, CW1
Hsieh, YY1
Chiu, WN1
Hu, JH1
Lu, SN1
Hung, CH1
Alakavuklar, MA1
Fuqua, C1
Luo, KL1
Underwood, RS1
Greenwald, I1
Elashiry, MM1
Elashiry, M1
Zeitoun, R1
Elsayed, R1
Tian, F1
Saber, SE1
Elashry, SH1
Tay, FR1
Cutler, CW1
O'Dowd, A1
Maciel, M1
Poole, ST1
Jobling, MG1
Rollenhagen, JE1
Woods, CM1
Sincock, SA1
McVeigh, AL1
Gregory, MJ1
Maves, RC1
Prouty, MG1
Holmes, RK1
Savarino, SJ1
Mor, MK1
Palevsky, PM1
Kaufman, JS1
Thiessen Philbrook, H1
Weisbord, SD1
Parikh, CR1
John, CM1
Phillips, NJ1
Jarvis, GA1
Kilburn, S1
Kapoor, M1
Chaturvedi, S1
Shaw, KJ1
Chaturvedi, V1
Kong, X1
Zhang, T1
Xiao, H1
Feng, X1
Tu, H1
Feng, J1
Sabet, M1
Tarazi, Z1
Griffith, DC1
Nguyen, F1
Guan, P1
Guerrero, DT1
Kolla, V1
Naraparaju, K1
Perry, LM1
Soberman, D1
Pressly, BB1
Alferiev, IS1
Chorny, M1
Brodeur, GM1
Gao, X2
Cheng, YH1
Enten, GA1
DeSantis, AJ1
Gaponenko, V1
Majetschak, M1
Kim, DY1
Choi, MJ1
Ko, TK1
Lee, NH1
Kim, OH1
Cheon, HG1
Cai, H1
Yip, V1
Lee, MV1
Wong, S1
Saad, O1
Ma, S1
Ljumanovic, N1
Khojasteh, SC1
Kamath, AV1
Shen, BQ1
Cuypers, ML1
Chanteux, H1
Gillent, E1
Bonnaillie, P1
Saunders, K1
Beckers, C1
Delatour, C1
Dell'Aiera, S1
Ungell, AL1
Nicolaï, J1
Knapp, AK1
Chen, A1
Griffin-Nolan, RJ1
Baur, LE1
Carroll, CJW1
Gray, JE1
Hoffman, AM1
Li, X5
Post, AK1
Slette, IJ1
Collins, SL1
Luo, Y1
Smith, MD1
Temitayo, GI1
Olawande, B1
Emmanuel, YO1
Timothy, AT1
Kehinde, O1
Susan, LF1
Ezra, L1
Joseph, OO1
Lev, S1
Desmarini, D1
Liuwantara, D1
Sorrell, TC1
Hawthorne, WJ1
Djordjevic, JT1
Verso, MG1
Costantino, C1
Marrella, A1
Immordino, P1
Vitale, F1
Amodio, E1
Wang, YD1
Yao, WL1
Xin, ZM1
Han, TT1
Wang, ZG1
Chen, L1
Cai, C1
Zhang, Y4
Ba, D1
Wen, S1
Tian, Q1
Lv, W1
Cheng, G1
Li, N1
Yue, XY1
Chu, WJ1
Chen, Q1
Choi, ES1
Zhao, X3
Zhou, HD1
Sun, XF1
Sharma, S2
Chhoker, S1
Xie, C1
Ong, EWY1
Tan, ZK1
Evans, S1
Weinheimer, CJ1
Kovacs, A1
Williams, JW1
Randolph, GJ1
Jiang, W1
Barger, PM1
Mann, DL1
Liu, J2
Kong, L1
Yu, X1
Feng, B1
Liu, D1
Zhao, B1
Mendes, GC1
Yuan, P1
Ge, D1
Wang, WM1
Fontes, EPB1
Shan, L1
He, P1
Katoh, T1
Sengoku, T1
Hirata, K1
Ogata, K1
Suga, H1
Shun, C1
Yong-Yi, J1
Mei-Li, C1
Shi-Li, L1
Jian-Bo, Z1
Dan-Li, W1
Zhi-Min, G1
Ibrahim, AM1
Zakhary, SY1
Amin, SAW1
Ugurlu, M1
Fornari, VJ1
Hartmann, MSM1
Vanni, JR1
Rodriguez, R1
Langaro, MC1
Pelepenko, LE1
Zaia, AA1
Nakanjako, D1
Zalwango, F1
Wairagala, P1
Luboga, F1
Andia Biraro, I1
Bukirwa, VD1
Mboowa, MG1
Cose, S1
Seeley, J1
Elliott, A1
Zhao, G1
Sun, P1
Hao, S2
Wang, X1
Qu, G1
Xing, Y1
Xu, X1
Maierhofer, M1
Rieger, V1
Mayr, T1
Liu, Y2
Zhang, Q1
Bigliardi, AP1
Fernandes, CLF1
Pinto, EA1
Dos Santos, M1
Garcia, EM1
Baisch, PRM1
Soares, MCF1
Muccillo-Baisch, AL1
da Silva Júnior, FMR1
Yu, W1
Ju, C1
Wang, K1
Zheng, Z1
Liu, H1
Gao, Y1
Martínez-Navarro, EM1
Cebrián-Tarancón, C1
Moratalla-López, N1
Lorenzo, C1
Alonso, GL1
Salinas, RM1
Bermúdez de Castro, JM1
Modesto-Mata, M1
Martín-Francés, L1
García-Campos, C1
Martínez de Pinillos, M1
Martinón-Torres, M1
Hasani, M1
Wu, F2
Warriner, K1
Kurz, M1
Gretzke, D1
Hörlein, R1
Turpault, S1
Atzrodt, J1
Derdau, V1
Yao, Y1
Ou, X1
Zhao, S1
Tian, B1
Jin, S1
Jiang, Z1
Zhou, Z1
Liu, M2
Jiang, GD1
Mou, LH1
Chen, JJ1
Li, ZY1
He, SG1
Reale, E1
Fustinoni, S1
Mercadante, R1
Polledri, E1
Hopf, NB1
Grant, PC1
Levy, K1
Lattimer, TA1
Depner, RM1
Kerr, CW1
Sato, J1
Merenda, MEZ1
Uemoto, AT1
Dos Santos, MP1
Barion, MRL1
Carciofi, AC1
de Paula Dorigam, JC1
Ribeiro, LB1
Vasconcellos, RS1
Waller, SB1
Peter, CM1
Hoffmann, JF1
Cleff, MB1
Faria de, RO1
Zani, JL1
Martins, BA1
Sande, D1
Solares, MD1
Takahashi, JA1
Yang, S2
Jia, Y1
Yin, C1
Zhao, R1
Ojha, M1
Wu, B1
Deepa, M1
Mo, J1
Au, DW1
Wan, MT1
Shi, J1
Zhang, G1
Winkler, C1
Kong, RY1
Seemann, F1
Bianco, M1
Calvano, CD1
Ventura, G1
Bianco, G1
Losito, I1
Cataldi, TRI1
Angiolella, L1
Staudt, A1
Duarte, PF1
Amaral, BPD1
Peixoto Andrade, BCO1
Simas, NK1
Correa Ramos Leal, I1
Sangenito, LS1
Santos, ALSD1
de Oliveira, D1
Junges, A1
Cansian, RL1
Paroul, N1
Siu, J1
Klingler, L1
Hung, CT1
Jeong, SH1
Smith, S1
Tingle, MD1
Wagner Mackenzie, B1
Biswas, K1
Douglas, RG1
Oza, AM1
Lorusso, D1
Aghajanian, C1
Oaknin, A1
Dean, A1
Colombo, N1
Weberpals, JI1
Clamp, AR1
Scambia, G1
Leary, A1
Holloway, RW1
Gancedo, MA1
Fong, PC1
Goh, JC1
O'Malley, DM1
Armstrong, DK1
Banerjee, S1
García-Donas, J1
Swisher, EM1
Cella, D1
Meunier, J1
Goble, S1
Cameron, T1
Maloney, L1
Mörk, AC1
Bedel, J1
Ledermann, JA1
Coleman, RL1
Vlek, SL1
Burm, R1
Govers, TM1
Vleugels, MPH1
Tuynman, JB1
Mijatovic, V1
Leicht, AS1
Connor, J1
Conduit, N1
Vaquera, A1
Gómez, MA1
McKay, JA1
Church, AL1
Rubin, N1
Emory, TH1
Hoven, NF1
Kuehn-Hajder, JE1
Nelson, MT1
Ramanna, S1
Auerbach, EJ1
Moeller, S1
Bolan, PJ1
Fox, NP1
Leonard, M1
Sjerps, MJ1
Chang, EF1
Hyun, S1
Saejio, A1
Shanmugam, S1
Liu, X1
Sun, M1
Bai, Z1
Jaque-Fernandez, F1
Beaulant, A1
Berthier, C1
Monteiro, L1
Allard, B1
Casas, M1
Rieusset, J1
Jacquemond, V1
Góngora-García, OR1
Aca-Aca, G1
Baz-Rodríguez, SA1
Monte, A1
Maganaris, C1
Baltzopoulos, V1
Zamparo, P1
Wang, Z2
Hou, Y1
Cai, L1
Tu, YJ1
Tan, B1
Jiang, L1
Wu, ZH1
Yu, HJ1
Li, XQ1
Yang, AD1
Titze, IR1
Palaparthi, A1
Mau, T1
González, MA1
Goiri, F1
Barandika, JF1
García-Pérez, AL1
Jatt, LP1
Gandhi, MM1
Guo, R1
Sukhija-Cohen, A1
Bhattacharya, D1
Tseng, CH1
Chew, KW1
Onwumere, J1
Pia Tek, J1
Budnyak, T1
Budnyk, S1
Karim, Z1
Thersleff, T1
Kuśtrowski, P1
Mathew, AP1
Slabon, A1
Guo, M1
Zhao, T1
Xing, Z1
Qiu, Y1
Pan, K1
Li, Z2
Zhou, W1
Ghassemi Tabrizi, S1
Arbuznikov, AV1
Jiménez-Hoyos, CA1
Kaupp, M1
Lin, MH2
Bulman, DM1
Remucal, CK1
Chaplin, BP1
Laguerre, A1
George, LA1
Gall, ET1
Emerson, MS1
Wang, H3
Maginn, EJ1
Margulis, CJ1
Li, H2
Feng, W1
Kang, X2
Yan, S1
Chao, M1
Mo, S1
Sun, W1
Lu, Y1
Chen, C1
Stevens, DM1
Adiseshaiah, P1
Dasa, SSK1
Potter, TM1
Skoczen, SL1
Snapp, KS1
Cedrone, E1
Patel, N1
Busman-Sahay, K1
Rosen, EP1
Sykes, C1
Cottrell, M1
Dobrovolskaia, MA1
Estes, JD1
Kashuba, ADM1
Stern, ST1
Özütemiz, C1
Neil, EC1
Tanwar, M1
Rubin, NT1
Ozturk, K1
Cayci, Z1
Duscha, BD1
Kraus, WE1
Jones, WS1
Robbins, JL1
Piner, LW1
Huffman, KM1
Allen, JD1
Annex, BH1
Mehmood, T1
Ahmad, I1
Bibi, S1
Mustafa, B1
Ali, I1
Dahal, RH1
Chaudhary, DK1
Kim, DU1
Kim, J1
Yeter, HH1
Gonul, I1
Guz, G1
Helvaci, O1
Korucu, B1
Akcay, OF1
Derici, U1
Arinsoy, T1
Neffati, R1
Judeinstein, P1
Rault, J1
Xu, Y1
Chai, X1
Ren, T1
Yu, S1
Fu, Q2
Ye, J1
Ge, X1
Song, J1
Yang, H2
El-Baba, TJ1
Lutomski, CA1
Kantsadi, AL1
Malla, TR1
John, T1
Mikhailov, V1
Bolla, JR1
Schofield, CJ1
Zitzmann, N1
Vakonakis, I1
Robinson, CV1
Langham, MC1
Caporale, AS1
Wehrli, FW1
Parry, S1
Schwartz, N1
den Boer, RB1
Jones, KI1
Ash, S1
van Boxel, GI1
Gillies, RS1
O'Donnell, T1
Ruurda, JP1
Sgromo, B1
Silva, MA1
Maynard, ND1
Sivieri, EM1
Eichenwald, EC1
Rub, D1
Abbasi, S1
Krahnert, I1
Bolze, A1
Gibon, Y1
Fernie, AR1
Huang, L1
Wan, Y1
Dang, Z1
Yang, P1
Yang, Q1
Wu, S2
Lin, CC1
Hsu, CT1
Liu, W2
Huang, SC1
Kortz, U1
Mougharbel, AS1
Chen, TY1
Hu, CW1
Lee, JF1
Wang, CC1
Liao, YF1
Li, LJ1
Li, L1
Peng, S1
Stimming, U1
Hebbar Kannur, K1
Yaqub, TB1
Pupier, C1
Héau, C1
Cavaleiro, A1
Yamamoto, S1
Ono, A1
Matsui, J1
Hoshino, N1
Akutagawa, T1
Miyashita, T1
Mitsuishi, M1
Patel, SM1
Smith, TG1
Morton, M1
Stiers, KM1
Seravalli, J1
Mayclin, SJ1
Edwards, TE1
Tanner, JJ1
Becker, DF1
Butcher, TW1
Yang, JL1
Hartwig, JF1
Yu, MF1
Xia, ZZ1
Yao, JC1
Feng, Z1
Li, DH1
Liu, T1
Cheng, GJ1
He, DL1
Li, XH1
Huurman, R1
Schinkel, AFL1
de Jong, PL1
van Slegtenhorst, MA1
Hirsch, A1
Michels, M1
Kataja, A1
Tarvasmäki, T1
Lassus, J1
Sionis, A1
Mebazaa, A1
Pulkki, K1
Banaszewski, M1
Carubelli, V1
Hongisto, M1
Jankowska, E1
Jurkko, R1
Jäntti, T1
Kasztura, M1
Parissis, J1
Sabell, T1
Silva-Cardoso, J1
Spinar, J1
Tolppanen, H1
Harjola, VP1
Carsetti, A1
Damiani, E1
Casarotta, E1
Scorcella, C1
Domizi, R1
Gasparri, F1
Gabbanelli, V1
Pantanetti, S1
Carozza, R1
Adrario, E1
Donati, A1
Almada, E1
Pariani, A1
Rivabella Maknis, T1
Hidalgo, F1
Vena, R1
Favre, C1
Larocca, MC1
Lu, ZY1
Jiang, WD1
Wu, P1
Kuang, SY1
Tang, L1
Yang, J1
Zhou, XQ1
Feng, L1
Leal, M1
Zampini, IC1
Mercado, MI1
Moreno, MA1
Simirgiotis, MJ1
Bórquez, J1
Ponessa, G1
Isla, MI1
Saliu, IO1
Amoo, ZA1
Khan, MF1
Olaleye, MT1
Rema, V1
Akinmoladun, AC1
Khan, AU1
Rahman, AU1
Yuan, Q1
Ahmad, A1
Khan, ZUH1
Mahnashi, MH1
Alyami, BA1
Alqahtani, YS1
Ullah, S1
Wirman, AP1
Gao, M1
Deng, L1
Zhang, K1
Wang, M1
Xia, Z1
Gao, D1
Balkissou, AD1
Poka-Mayap, V1
Massongo, M1
Djenabou, A1
Endale-Mangamba, LM1
Olomo, EJ1
Boulleys-Nana, JR1
Diffo-Sonkoue, L1
Adidigue-Ndiome, R1
Alexandra, AJE1
Haman-Wabi, AB1
Adama, S1
Iddi-Faical, A1
Pefura-Yone, EW1
Zhao, Q1
Tong, W1
Ge, C1
Zhao, D1
Norbäck, D1
Li, B1
Zhao, Z1
Huang, C1
Zhang, X1
Qian, H1
Yang, X1
Sun, Y1
Sundell, J1
Deng, Q1
Kim, HJ1
Jeon, JW1
Hwang, SM1
Chu, KI1
Cha, YH1
Kwak, YD1
Choi, SD1
Aslam, M1
Kim, CG1
Zhou, J1
Yang, E1
Yang, W1
McPherson, S1
Wilkinson, N1
Tiniakos, D1
Wilkinson, J1
Burt, AD1
McColl, E1
Stocken, DD1
Steen, N1
Barnes, J1
Goudie, N1
Stewart, S1
Bury, Y1
Mann, D1
Anstee, QM1
Day, CP1
Takeda, K1
Kitade, M1
Aihara, Y2
Douhara, A2
Murad, HA1
Gazzaz, ZJ1
Ali, SS1
Ibraheem, MS1
Piecha, F1
Mandorfer, M1
Peccerella, T1
Ozga, AK1
Poth, T1
Vonbank, A1
Seitz, HK1
Rausch, V1
Reiberger, T1
Mueller, S1
Parreira, NA1
Ramalho, FS1
Augusto, MJ1
Silva, DM1
Prado, CM1
Elias Júnior, J1
Rodrigues, V1
Ramalho, LNZ1
Karimi, J1
Mohammadalipour, A1
Sheikh, N1
Khodadadi, I1
Hashemnia, M1
Goudarzi, F1
Khanjarsim, V1
Solgi, G1
Hajilooi, M1
Bahabadi, M1
Kheiripour, N1
Hedayatyanfard, K1
Fialla, AD1
Schaffalitzky de Muckadell, OB1
Bie, P1
Thiesson, HC1
Wu, L1
Zhou, PQ1
Xie, JW1
Zhu, R1
Zhou, SC1
Wang, G1
Wu, ZX1
Thomas, RG1
Moon, MJ1
Kim, JH1
Lee, JH1
Jeong, YY1
Aoudjehane, L1
Boelle, PY1
Bisch, G1
Delelo, R1
Paye, F1
Scatton, O1
Housset, C1
Becquart, J1
Calmus, Y1
Conti, F1
Madro, A2
Kurzepa, J2
Celinski, K2
Slomka, M1
Czechowska, G2
Kazmierak, W1
Buszewicz, G1
Ciesielka, M1
Madro, R1
Korolczuk, A1
Wojcicka, G1
Dudka, J1
Bojarska, A1
Brzozowski, T1
Colmenero, J1
Bataller, R2
Sancho-Bru, P2
Domínguez, M1
Moreno, M2
Forns, X1
Bruguera, M1
Arroyo, V2
Brenner, DA2
Ginès, P2
Gonzalo, T1
Kok, RJ1
van Beuge, M1
Swart, J1
Prakash, J1
Temming, K1
Fondevila, C1
Beljaars, L1
Lacombe, M1
van der Hoeven, P1
Poelstra, K1
Brooks, R1
Huang, HC1
Chang, CC1
Wang, SS1
Lee, FY2
Teng, TH1
Lee, JY1
Lin, HC2
Chuang, CL1
Lee, SD2
Sipal, S1
Halici, Z1
Kiki, I1
Polat, B1
Albayrak, A1
Albayrak, F1
Karakus, E1
Aksak, S1
Ozturk, B1
Gundogdu, C1
Walch, JD1
Carreño, FR1
Cunningham, JT1
Agasti, AK1
Mahajan, AU1
Phadke, AY1
Nathani, PJ1
Sawant, P1
Shirai, Y1
Fukui, H1
Terui, Y1
Saito, T1
Watanabe, H1
Togashi, H1
Kawata, S1
Kamada, Y1
Sakuta, S1
Croquet, V1
Moal, F1
Veal, N1
Oberti, F1
Roux, J1
Vuillemin, E1
Gallois, Y1
Douay, O1
Chappard, D1
Calès, P1
Zhang, YJ1
Yang, XS1
Wu, PS1
Zhang, XF1
Chen, XQ1
Yu, ZX1
Blendis, LM1
Wong, F4
De, BK1
Bandyopadhyay, K1
Das, TK1
Das, D1
Biswas, PK1
Majumdar, D1
Mandal, SK1
Ray, S1
Dasgupta, S1
Tripathi, D1
Therapondos, G2
Lui, HF1
Johnston, N1
Webb, DJ3
Hayes, PC3
Yokohama, S2
Yoneda, M2
Haneda, M2
Okamoto, S2
Okada, M2
Aso, K2
Hasegawa, T2
Tokusashi, Y2
Miyokawa, N2
Nakamura, K2
Castaño, G4
Viudez, P3
Sookoian, S4
Wei, YH1
Jun, L1
Qiang, CJ1
García, SI1
González, C1
Pirola, CJ1
Spiering, W1
Kroon, AA1
de Leeuw, PW1
Fernández, MA1
Tamaki, Y1
Aoshima, M1
Hol, L1
Benjaminov, F1
Tarsitano, CA1
Paffaro, VA1
Pauli, JR1
da Silva, GH1
Saad, MJ1
Salgado, I1
da Cruz-Höfling, MA1
Hyslop, S1
Ibañez, P1
Solis, N1
Pizarro, M1
Aguayo, G1
Duarte, I1
Miquel, JF1
Accatino, L1
Arrese, M1
El-Demerdash, E1
Salam, OM1
El-Batran, SA1
Abdallah, HM1
Shaffie, NM1
Moreau, R1
Lebrec, D1
Newby, DE3
Jalan, R3
Masumori, S1
Boon, NA1
Schneider, AW1
Kalk, JF1
Klein, CP1
Girgrah, N1
Liu, P2
Collier, J1
Blendis, L2
Helmy, A1
González-Abraldes, J1
Albillos, A1
Bañares, R1
Del Arbol, LR1
Moitinho, E1
Rodríguez, C1
González, M1
Escorsell, A1
García-Pagán, JC1
Bosch, J1
Yang, YY1
Huang, YT1
Lee, TY1
Hou, MC1
Liu, RS1
Chang, FY1
Frider, B1
Gustavo, C1
Pedro, V1
Bernardo, F1
Silvia, S1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Long-Term Administration of Oral Losartan on Hepatic Fibrogenesis and Gene Expression in Chronic Hepatitis C With Significant Liver Fibrosis.[NCT00298714]Phase 420 participants Interventional2003-03-31Completed
Beneficial Effect of Angiotensin-blocking Agent Candesartan on Alcoholic Liver Fibrosis: A Randomized Controlled Trial[NCT00990639]Phase 1/Phase 285 participants (Actual)Interventional2005-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for losartan and Liver Cirrhosis

ArticleYear
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
Transduction of antinatriuretic signals in renal proximal tubular cells in cirrhosis: introduction to novel approaches to the treatment of sodium retention.
    Journal of hepatology, 1998, Volume: 28, Issue:6

    Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; H

1998

Trials

10 trials available for losartan and Liver Cirrhosis

ArticleYear
Angiotensin receptor blocker alleviates liver fibrosis by altering the mechanotransduction properties of hepatic stellate cells.
    American journal of physiology. Gastrointestinal and liver physiology, 2022, 04-01, Volume: 322, Issue:4

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Hepatic Stellat

2022
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.
    PloS one, 2017, Volume: 12, Issue:4

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Drug Administration Sched

2017
Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C.
    American journal of physiology. Gastrointestinal and liver physiology, 2009, Volume: 297, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Administration, Oral; A

2009
Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease.
    Journal of digestive diseases, 2013, Volume: 14, Issue:5

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Female; Follow-Up Studies;

2013
Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2002, Volume: 36, Issue:4 Pt 1

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Female; Hepatitis C, Chronic; Humans; Liv

2002
Portal pressure response to losartan compared with propranolol in patients with cirrhosis.
    The American journal of gastroenterology, 2003, Volume: 98, Issue:6

    Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II; Antihypertensive Agents; Esophageal and Gastric

2003
Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
    Hepatology (Baltimore, Md.), 1999, Volume: 29, Issue:2

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Bilirubin; Female; Hemodynam

1999
Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.
    Gastroenterology, 2001, Volume: 121, Issue:2

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Creatinine; Female; Glomerular

2001
The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis.
    Hepatology (Baltimore, Md.), 2002, Volume: 35, Issue:6

    Topics: Aldosterone; Antihypertensive Agents; Ascites; Blood Volume; Homeostasis; Humans; Liver Cirrhosis; L

2002

Other Studies

40 other studies available for losartan and Liver Cirrhosis

ArticleYear
Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2022, Volume: 41, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting En

2022
Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells.
    Proceedings of the National Academy of Sciences of the United States of America, 2023, 05-09, Volume: 120, Issue:19

    Topics: Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Humans; Liver Cirrhosis; Liver Neoplasms; Los

2023
Periostin cross‑reacts with the renin‑angiotensin system during liver fibrosis development.
    Molecular medicine reports, 2017, Volume: 16, Issue:5

    Topics: Angiotensin II; Animals; Cell Adhesion Molecules; Collagen Type I; Collagen Type I, alpha 1 Chain; G

2017
Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2017, Sep-21, Volume: 50, Issue:11

    Topics: Alanine Transaminase; Ammonia; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Bip

2017
Pharmacological decrease of liver stiffness is pressure-related and predicts long-term clinical outcome.
    American journal of physiology. Gastrointestinal and liver physiology, 2018, 10-01, Volume: 315, Issue:4

    Topics: Adult; Aged; Animals; Antihypertensive Agents; Arterial Pressure; Elasticity Imaging Techniques; Fem

2018
The comparative efficacy of renin-angiotensin system blockers in schistosomal hepatic fibrosis.
    Experimental parasitology, 2018, Volume: 191

    Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals;

2018
Protective effects of combined Losartan and Nilotinib on carbon tetrachloride (CCl
    Drug and chemical toxicology, 2020, Volume: 43, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Carbon Tetrachloride; Drug Therapy, Combination; L

2020
Activation of RAAS in a rat model of liver cirrhosis: no effect of losartan on renal sodium excretion.
    BMC nephrology, 2018, 09-19, Volume: 19, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cholestasis; Disease Models, Animal; Kidney; Liver

2018
Effects of Yinchenhao decoction on self-regulation of renin-angiotensin system by targeting angiotensin converting enzyme 2 in bile duct-ligated rat liver.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2015, Volume: 35, Issue:4

    Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Gene Expression Regulation; Liver; Liver Cir

2015
Effectiveness of Losartan-Loaded Hyaluronic Acid (HA) Micelles for the Reduction of Advanced Hepatic Fibrosis in C3H/HeN Mice Model.
    PloS one, 2015, Volume: 10, Issue:12

    Topics: Animals; Biological Transport; Cell Line; Cell Survival; Collagen; Disease Models, Animal; Drug Carr

2015
Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts.
    Laboratory investigation; a journal of technical methods and pathology, 2016, Volume: 96, Issue:6

    Topics: Actins; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cells, Cultured; Collagen Type I; Drug E

2016
Effects of renin-angiotensin system inhibitors on fibrosis in patients with alcoholic chronic pancreatitis.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2016, Volume: 67, Issue:1

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Female; Humans; Liver Cirrhosis; Losart

2016
The effect of the angiotensin II receptor, type 1 receptor antagonists, losartan and telmisartan, on thioacetamide-induced liver fibrosis in rats.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2016, Volume: 67, Issue:4

    Topics: Alanine Transaminase; Alkaline Phosphatase; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-I

2016
Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Disease Progression; Drug Deliver

2010
Management of varices in cirrhosis.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Angiotensin II Type 1 Receptor Blockers; Esophageal and Gastric Varices; Humans; Hypertension, Porta

2010
The roles of angiotensin II receptors in the portosystemic collaterals of portal hypertensive and cirrhotic rats.
    Journal of vascular research, 2012, Volume: 49, Issue:2

    Topics: Animals; Collateral Circulation; Down-Regulation; Guanidines; Hypertension, Portal; Imidazoles; Liga

2012
Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: stereology, histopathology, and electron microscopy.
    Journal of molecular histology, 2012, Volume: 43, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Imidazoles; Liver

2012
Intracerebroventricular losartan infusion modulates angiotensin II type 1 receptor expression in the subfornical organ and drinking behaviour in bile-duct-ligated rats.
    Experimental physiology, 2013, Volume: 98, Issue:4

    Topics: Animals; Bile Ducts; Disease Models, Animal; Drinking; Drinking Behavior; Infusions, Intraventricula

2013
Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
    Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:4

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Communication; Disease Models

2013
Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension.
    Journal of hepatology, 2002, Volume: 37, Issue:6

    Topics: Alanine Transaminase; Alkaline Phosphatase; Angiotensin Receptor Antagonists; Animals; Bile Ducts; B

2002
Effects of angiotensin II and losartan on the growth and proliferation of hepatic stellate cells.
    Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2003, Volume: 23, Issue:3

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Division; Cells, Cultured; Dr

2003
Does losartan work after all?
    The American journal of gastroenterology, 2003, Volume: 98, Issue:6

    Topics: Antihypertensive Agents; Humans; Hypertension, Portal; Liver Cirrhosis; Losartan; Propranolol; Rando

2003
Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:2

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Female; Hemodynamics; Humans; Hypertensio

2004
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.
    Hepatology (Baltimore, Md.), 2004, Volume: 40, Issue:5

    Topics: Adult; Angiotensin Receptor Antagonists; Biomarkers; Fatty Liver; Female; Ferritins; Hepatitis; Huma

2004
Losartan in preascitic cirrhosis.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:11

    Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Female; Hepatic Veins; Humans; Hyp

2004
Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats.
    Digestive diseases and sciences, 2004, Volume: 49, Issue:10

    Topics: Alanine Transaminase; Angiotensin II Type 1 Receptor Blockers; Animals; Aspartate Aminotransferases;

2004
A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:3

    Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Chromatography, Hi

2005
A116C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:11

    Topics: Adenine; Alleles; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cytosine; Heart

2005
Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study.
    World journal of gastroenterology, 2005, Dec-28, Volume: 11, Issue:48

    Topics: Adult; Aged; Female; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Losartan; Male; Middle Ag

2005
Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis.
    World journal of gastroenterology, 2006, Jan-14, Volume: 12, Issue:2

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Fatty Liver; Female; Humans; Liver; Liver Cirr

2006
The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:3

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Ascites; Dose-Response Relationship,

2006
Hepatic morphological alterations, glycogen content and cytochrome P450 activities in rats treated chronically with N(omega)-nitro-L-arginine methyl ester (L-NAME).
    Cell and tissue research, 2007, Volume: 329, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Chronic

2007
Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Choline Deficiency; Disease Models, Animal; Fatty

2007
Inhibition of the renin-angiotensin system attenuates the development of liver fibrosis and oxidative stress in rats.
    Clinical and experimental pharmacology & physiology, 2008, Volume: 35, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid

2008
Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems.
    Cardiovascular research, 1998, Volume: 38, Issue:1

    Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Fem

1998
Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis.
    Gut, 2000, Volume: 46, Issue:1

    Topics: Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Ascites; Dose-Response Relationship,

2000
Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis.
    Gastroenterology, 2000, Volume: 118, Issue:3

    Topics: Adult; Angiotensin II; Antihypertensive Agents; Blood Vessels; Disease Progression; Dose-Response Re

2000
Losartan and renal sodium handling.
    Gut, 2000, Volume: 47, Issue:4

    Topics: Angiotensin II; Antihypertensive Agents; Humans; Liver Cirrhosis; Losartan; Natriuresis

2000
Effect of 1-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension.
    Journal of hepatology, 2002, Volume: 36, Issue:5

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Blotting, Western; Common Bile Duct; Enzyme Inhibi

2002
Discussion on randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.
    Gastroenterology, 2002, Volume: 122, Issue:5

    Topics: Antihypertensive Agents; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Losartan; Male; Prop

2002